Insulin Resistance, Metabolic Disease, Obesity, PreDiabetes, Type 2 Diabetes
Conditions
Brief summary
This research study collects health-related information and blood samples to better understand how body composition, lifestyle habits, and diet influence meta-inflammatory monocytes (MiMos) in adolescents. The hypothesis of this study is that adolescents at risk for metabolic disease have enhanced MiMo related activities leading to insulin resistance.
Interventions
None listed
Sponsors
University of Michigan
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
14 Years to 18 Years
Healthy volunteers
Yes
Inclusion criteria
* Between 14 and 18 years of age * Tanner stage 4 or 5 (mature adult stage of puberty) * Normal weight (BMI ≥ 5th percentile \& \< 85th percentile), overweight (BMI \> 86th percentile) \& \< 94th percentile), obese weight (BMI percentile ≥ 95th percentile), and/or pre-diabetes (HbA1c \> 5.7%) * For Type 2 Diabetes cohort, diagnosis of Type 2 Diabetes
Exclusion criteria
* Currently pregnant * Use medications known to affect glucose metabolism (immunosuppressive medications, cancer medications, or high dose steroids), unless prescribed for Type 2 Diabetes management * Prior diagnosis of autoimmune disease, cancer, or a cognitive or perceptual disability that would inhibit following directions of study staff * Allergies or intolerance to milk, soy, or palm oil
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Glucose (OGTT) | 120 minutes | Plasma Glucose (mg/dL) will be measured prior to, and throughout, an Oral Glucose Tolerance Test (OGTT). Measurements will be taken at baseline (fasting) and 30, 60, 90 and 120 minutes after consumption of glucose dose |
| Insulin (OGTT) | 120 minutes | Plasma Insulin (µU/mL) will be measured prior to, and throughout, an Oral Glucose Tolerance Test (OGTT). Measurements will be taken at baseline (fasting) and 30, 60, 90 and 120 minutes after consumption of glucose dose |
| Glucose (MMTT) | 180 minutes | Plasma Glucose (mg/dL) will be measured prior to, and throughout, a Mixed Meal Tolerance Test (MMTT). Measurements will be taken at baseline (fasting) and 30, 60, 90, 120 and 180 minutes after consumption of high fat shake. |
| Insulin (MMTT) | 180 minutes | Plasma Insulin (µU/mL) will be measured prior to, and throughout, a Mixed Meal Tolerance Test (MMTT). Measurements will be taken at baseline (fasting) and 30, 60, 90, 120 and 180 minutes after consumption of high fat shake. |
| Monocyte /macrophage populations by flow cytometry | 180 minutes | Frequencies by flow cytometry. Measurements will be taken at baseline sample and 180 minutes after consumption of high fat shake |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Free fatty acids (MMTT) | 180 minutes | Serum Free fatty acids (mmol/L) will be measured prior to, and throughout, a Mixed Meal Tolerance Test (MMTT). Measurements will be taken at baseline (fasting) and 30, 60, 90, 120 and 180 minutes after consumption of high fat shake |
| Triglycerides (MMTT) | 180 minutes | Serum Triglycerides (mg/dL) will be measured prior to, and throughout, a Mixed Meal Tolerance Test (MMTT). Measurements will be taken at baseline (fasting) and 30, 60, 90, 120 and 180 minutes after consumption of high fat shake |
Countries
United States
Contacts
CONTACTThe Singer Lab Team
PRINCIPAL_INVESTIGATORKanakadurga Singer, MA, MD
University of Michigan
Outcome results
None listed